[Interview] Inventage Lab CEO Kim Ju-hee discusses strategic partnership by separating DrugFluidic and GeneFluidic 슬롯사이트 2025년s
[by Kang, In Hyo] Inventage Lab, a company specializing in drug delivery system (DDS) development, has initiated the development of an ‘antibody-drug conjugate (ADC) 슬롯사이트 2025년’ based on its next-generation DDS 슬롯사이트 2025년.
In an interview with <THE BIO, Kim Ju-hee, CEO of Inventage Lab, who attended the ‘2025 J.P. Morgan Healthcare Conference,’ the world’s largest pharmaceutical and biotechnology investment event held in San Francisco, USA, on January 13 (local time), stated, “We are developing the ADC 슬롯사이트 2025년 as the company’s third DDS 슬롯사이트 2025년 and positioning it as a secret weapon. It is currently in the early stages of research and development (R&D).”
“The ADC 슬롯사이트 2025년 is the company’s third self-developed DDS 슬롯사이트 2025년, following the company’s main DDS 슬롯사이트 2025년s, the ‘IVL-DrugFluidic 슬롯사이트 2025년’ and the ‘IVL-GeneFluidic 슬롯사이트 2025년,’” Kim further stated.
Inventage Lab, which entered the KOSDAQ market through a technology special listing in November 2022, has participated in the JP Morgan Healthcare Conference for three consecutive 슬롯사이트 2025년s, from 2023 to this 슬롯사이트 2025년. “Since the KOSDAQ listing, the company has become more recognized, and its visibility has increased,” Kim remarked. “We’ve been attending the JP Morgan Healthcare Conference annually since participation in the ‘Biotech Showcase (BTS)’.”
“The JP Morgan Healthcare Conference is a major global partnering event held in January, shortly after global pharmaceutical companies close their books for the 슬롯사이트 2025년,” Kim further commented. “From the perspective of global pharmaceutical companies, this period represents a time of ‘sowing’, meaning that various discussions and business meetings are actively held to identify biotech companies with noteworthy technologies and competitiveness.”
Inventage Lab is set to hold 25 business development (BD) meetings during the JP Morgan Healthcare Conference. Kim is actively conducting partnering meetings focused on the company’s two primary 슬롯사이트 2025년s: the DrugFluidic 슬롯사이트 2025년 and the GeneFluidic 슬롯사이트 2025년.
“This year, we are having more meetings focused on the GeneFluidic 슬롯사이트 2025년 compared to the DrugFluidic 슬롯사이트 2025년,” Kim stated. “With the growing interest in lipid nanoparticles (LNPs) and nanoparticles, which typically range from 1 to 100 nanometers (nm), there appears to be increasing interest in our company as we are preparing to manufacture equipment that uses technologies.”
The GeneFluidic 슬롯사이트 2025년, used for genetic material drug delivery, is capable of producing lipid nanoparticles (LNPs), which serve as DDS delivery vehicles for messenger ribonucleic acid (mRNA) vaccines and gene therapy drugs, both of which are gaining attention as next-generation treatments. “It seems that the market’s interest in genetic material drug delivery is growing,” Kim expressed. “Since last year, there has been an increase in inquiries and orders for the 슬롯사이트 2025년 in Korea as well.”
In particular, Kim emphasized, “Interest in DDS related to gene therapy is growing globally, but there are few companies with the technology to implement it.” She further highlighted, “We have the competitiveness to develop genetic material medicines by equipping the GeneFluidic 슬롯사이트 2025년 and supplying them directly to customers (companies) or through contract development and manufacturing (CDMO) services.”
Another key 슬롯사이트 2025년 of Inventage Lab, the DrugFluidic 슬롯사이트 2025년, is designed for developing and manufacturing ‘long-acting injections (LAI)’ by applying ‘microfluidics’ technology in pharmaceutical R&D. This 슬롯사이트 2025년 ensures stable drug release control through the use of ‘microspheres’ measuring 30-40 µm, made from biopolymers such as sutures that naturally decompose in the body.
Long-acting injections are treatments designed to provide a continuous therapeutic effect, even when administered just once a month or every three months. These injections are formulated to release the drug gradually from the muscles into the bloodstream. Additionally, 슬롯사이트 2025년 Lab is working on developing a long-acting injection for oral administration.
In January 2024, 슬롯사이트 2025년 Lab entered into a research agreement with Yuhan Corporation and is currently working on the development of 1-month and 3-month sustained-release formulations of ‘semaglutide (development code IVL3021),’ a glucagon-like peptide 1 (GLP-1) receptor agonist (RA), and ‘tirzepatide (development code IVL3024),’ a GIP/GLP-1 series component.
Semaglutide is the active ingredient in Novo Nordisk’s global blockbuster obesity treatment, ‘Wegovy.’ Additionally, ‘Zepbound,’ a drug developed by Eli Lilly, in an obesity treatment that is based on tirzepatide.
“While semaglutide and tirzepatide, which are administered as weekly injections, demonstrate strong efficacy, their pharmacokinetic profiles show that the drug concentration rises quickly during a short ‘effective period’ but then decreases sharply due to their half-life, leading to an extended effective period,” Kim explained. “These pharmacokinetic characteristics contribute to the occurrence of side effects.”
“The long-acting injection we are developing offers the advantage of a low initial burst (toxicity) in its drug release pattern, ensuring that the drug’s efficacy is maintained at a stable drug concentration over an extended period, providing consistent effectiveness after administration,” she further emphasized. “In the case of obesity, discontinuing the drug administration due to side effects is not an option. Ultimately, the key is to minimize side effects while ensuring the drug’s effects last for a prolonged time.”
Lastly, Kim concluded by stating, “Last 슬롯사이트 2025년 was a significant one for us, as we secured important global contracts.” She added, “With our R&D progressing well, our goal is to advance a GLP-1-based long-acting obesity treatment candidate into the clinical stage. We are committed to achieving positive outcomes and ensuring that the long-acting injection co-development contract for a peptide novel drug candidate, signed with the multinational pharmaceutical company Boehringer Ingelheim last 슬롯사이트 2025년, is finalized as a main contract this 슬롯사이트 2025년.”